ASX-listed PharmAust’s fully-owned subsidiary, Epichem, has appointed experienced pharmaceutical and healthcare executive, Colin La Galia, as its new CEO and he will replace Dr Martine Keenan, who will step down from the role to resume her former position as Epichem Head of Drug Discovery and join the company’s board. Epichem is a successful contract medicinal chemistry company that is forecasting $4.2m revenues for the current financial year.
14/10/2019 - 16:26
Epichem appoints new CEO to steer drug business
By Matt Birney
14/10/2019 - 16:26
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX